Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Johnson & Johnson acquired Centocor in a $4.9 billion stock-for-stock transaction, gaining full ownership of Remicade (infliximab), which had been approved for Crohn's disease in 1998 and later became one of the world's best-selling biologic drugs.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Johnson & Johnson / Centocor Inc. (this deal) | 1999 | $4.9B | 92 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $9.0B | 96 |
| Johnson & Johnson / Cougar Biotechnology, Inc. | 2009 | $970M | 91 |
| Johnson & Johnson / Actelion Ltd | 2017 | $30.0B | 90 |
| Johnson & Johnson / Aragon Pharmaceuticals Inc. | 2013 | $1.0B | 89 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $350M | 83 |
| Johnson & Johnson / Genmab A/S | 2012 | $3.0B | 77 |
← Browse all deals · How we score deals
More: 1999 deals · Johnson & Johnson deals · Gastroenterology deals